Koshiro Fukuda

9PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsComposite and hybrid materials
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 21, 2025
Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.

Koshiro Fukuda, Hiroki Osumi, Akira Ooki

|Apr 10, 2025
Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency.

Koshiro Fukuda, Akiyoshi Kasuga, Yasuyuki Shigematsu

|Jul 27, 2024
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study.

Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami

|Nov 06, 2023
Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study.

Keitaro Shimozaki, Izuma Nakayama, Daisuke Takahari

|Jul 06, 2023
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.

Koshiro Fukuda, Hiroki Osumi, Koichiro Yoshino

|Mar 11, 2023
Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation.

Shohei Udagawa, Akira Ooki, Eiji Shinozaki

Pageof 2

Frequent Collaborators

5 joint publications

Hiroki Osumi

4 joint publications

Keisho Chin

4 joint publications

Eiji Shinozaki

4 joint publications

Kensei Yamaguchi